Carol Chen, Marketing and Product Manager
In the UK, there are over 15 million hypertensive patients. Chronic disease prevention and control urgently needs to shift from passive treatment to early screening and accurate identification, to reduce the burden on the medical system and improve patients' quality of life.
The precise screening of secondary hypertension as the starting point, deeply explain the breakthrough progress of Snibe's original technology in the detection of markers such as aldosterone, and bring new perspectives and solutions for UK hypertension prevention and control through the practical experience of Chinese multi-center clinical studies; we will also focus on multiple chronic disease scenarios such as osteoporosis prediction and treatment monitoring, endocrine and metabolic system toxicity prediction during tumor treatment, and the application practice of the GADA algorithm model aimed at hepatitic cancer screening developed based on 30,000 samples in Chinese hepatitis B population, sharing future innovative solutions for disease prevention and control from the perspective of an in vitro diagnostic enterprise. Sharing the cross-regional diagnostic inspiration and cooperation opportunities.